Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Billion dollar babies-biotech drugs as blockbusters

Article Abstract:

The biotech drugs like the HIV drug-Atripla, HPV vaccine, monoclonal antibodies for cancer treatment are fetching tremendous revenues and have attained a biopharmaceutical blockbuster status. The biotech industry aims to target broad-based markets with a large patient population.

Author: Lawerence, Stacy
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
Industry overview

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Crystal gazing: Biotech's financial outlook

Article Abstract:

A leading biotechnology analyst has given his views on the future of the biotechnology industry. Biotechnology is a research and development driven enterprise and hence investors should pay more attention to management compensation in the future.

Author: Schmidt, Eric, Strupp, David J.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Biotechnology

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Getting dumped

Article Abstract:

Industry insiders have provided some alternatives for the best practice when a product is returned or discontinued by a licensee.

Author: Huggett, Brady
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
Market size

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Biotechnology industry, Biotechnology industries, Forecasts and trends, Market trend/market analysis, Industry sales and revenue, Industry forecasts
Similar abstracts:
  • Abstracts: Covering the spectrum. Getting tough. The case for consolidation
  • Abstracts: Insights into US public biotech sector using patenting trends. Navigating the future(s) of biotech intellectual property
  • Abstracts: The policy outlook from the Hill. Action needed to harmonize regulation of low-level presence of biotech traits
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.